July 8, 2021 9:28 AM 27 seconds read

Vor Biopharma, Janssen Team Up To Develop Combination Therapies For Acute Myeloid Leukemia

by Vandana Singh Benzinga Editor
Follow
Comments
  • Vor Biopharma Inc VOR has collaborated with Janssen Biotech Inc, a unit of Johnson & Johnson JNJ.
  • Under the terms of the collaboration, Vor Biopharma will investigate the combination of Vor's engineered hematopoietic stem cell (eHSC) platform with one of Janssen's bi-specific antibodies for acute myeloid leukemia (AML).  
  • The collaboration agreement provides that each company retains all rights and ownership to their respective programs and platforms.
  • Price Action: VOR shares closed at $18.15 on Wednesday.
JNJ Logo
JNJJohnson & Johnson
$153.75-0.40%

Stock Score Locked: Want to See it?

Benzinga Rankings give you vital metrics on any stock – anytime.

Reveal Full Score
Edge Rankings
Momentum
64.93
Growth
50.81
Quality
22.95
Value
20.30
Price Trend
Short
Medium
Long
Overview
VOR Logo
VORVor Biopharma Inc
$0.72995.63%
Market News and Data brought to you by Benzinga APIs

© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Posted In:
BiotechNewsHealth CareContractsSmall CapGeneralBriefsmyeloid leukemia

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga

© 2025 Benzinga | All Rights Reserved